Overall, these mutations appear unlikely to drive cancer (Table 2), though discordant predictions (e.g., MSH2 c.2744A>G was classified as pathogenic by SIFT) underscore the limitations of in silico tools and the need for functional validation. This evidence concerns the gene MSH2 and cancer.